{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:16:12Z","timestamp":1793232972997,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Eng"],"DOI":"10.1186\/s13036-026-00627-y","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:24:25Z","timestamp":1770449065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Self-assembled PEGylated nanoparticles based on Elafibranor derivative 3d for the treatment of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Jiajia","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Galons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuou","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"3","key":"627_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VWS Wong","year":"2023","unstructured":"Wong VWS, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u201352.","journal-title":"J Hepatol"},{"issue":"2","key":"627_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): A Multi-systemic disease beyond the liver. J Clin Translational Hepatol. 2022;10(2):329\u201338.","journal-title":"J Clin Translational Hepatol"},{"issue":"4","key":"627_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hep Intl. 2023;17(4):773\u201391.","journal-title":"Hep Intl"},{"issue":"7","key":"627_CR4","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):S78\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"627_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702.","journal-title":"Gut"},{"issue":"7","key":"627_CR6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375\u201382.","journal-title":"Gut"},{"issue":"6","key":"627_CR7","first-page":"729","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ, Resmetirom. First Approval Drugs. 2024;84(6):729\u201335.","journal-title":"First Approval Drugs"},{"issue":"9","key":"627_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, et al. Efficacy and safety of Elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805.","journal-title":"N Engl J Med"},{"key":"627_CR9","doi-asserted-by":"publisher","first-page":"115510","DOI":"10.1016\/j.ejmech.2023.115510","volume":"257","author":"C Xiang","year":"2023","unstructured":"Xiang C, et al. Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo. Eur J Med Chem. 2023;257:115510.","journal-title":"Eur J Med Chem"},{"key":"627_CR10","doi-asserted-by":"crossref","unstructured":"Al-Shadidi J, et al. Polyethylene glycol-mediated functionalization of nanodelivery systems for improving their pharmacokinetic profile and anticancer efficacy. Int J Polym Mater Polym Biomater. 2024.","DOI":"10.1080\/00914037.2024.2383413"},{"issue":"7","key":"627_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1021\/ar500055s","volume":"47","author":"QD Hu","year":"2014","unstructured":"Hu QD, Tang GP, Chu PK. Cyclodextrin-Based Host-Guest supramolecular nanoparticles for delivery: from design to applications. Acc Chem Res. 2014;47(7):2017\u201325.","journal-title":"Acc Chem Res"},{"issue":"29","key":"627_CR12","doi-asserted-by":"publisher","first-page":"10835","DOI":"10.1080\/10408398.2023.2229433","volume":"64","author":"CT Wen","year":"2024","unstructured":"Wen CT, et al. Advances in lipo-solubility delivery vehicles for curcumin: bioavailability, precise targeting, possibilities and challenges. Crit Rev Food Sci Nutr. 2024;64(29):10835\u201354.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"627_CR13","doi-asserted-by":"crossref","unstructured":"Tan Y, et al. Gelatin as a bioactive nanodelivery system for functional food applications. Food Chem. 2023:423.","DOI":"10.1016\/j.foodchem.2023.136265"},{"issue":"1","key":"627_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.apsb.2021.08.012","volume":"12","author":"SW Fu","year":"2022","unstructured":"Fu SW, et al. Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy. Acta Pharm Sinica B. 2022;12(1):92\u2013106.","journal-title":"Acta Pharm Sinica B"},{"key":"627_CR15","doi-asserted-by":"crossref","unstructured":"Zhang S, et al. Compound 3d attenuates metabolic dysfunction-associated steatohepatitis via peroxisome proliferator-activated receptor pathway activation and Inhibition of inflammatory and apoptotic signaling. Metabolites. 2025;15(5).","DOI":"10.3390\/metabo15050296"},{"issue":"6","key":"627_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/17460441.2023.2211801","volume":"18","author":"B Rocha","year":"2023","unstructured":"Rocha B, et al. Promising strategies for improving oral bioavailability of poor water-soluble drugs. Expert Opin Drug Discov. 2023;18(6):615\u201327.","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"627_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/17460441.2020.1750591","volume":"15","author":"FLO Da Silva","year":"2020","unstructured":"Da Silva FLO, et al. Nanonization techniques to overcome poor water-solubility with drugs. Expert Opin Drug Discov. 2020;15(7):853\u201364.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"627_CR18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1080\/10717544.2017.1365393","volume":"24","author":"H Zhang","year":"2017","unstructured":"Zhang H, et al. Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfide bond Bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy. Drug Deliv. 2017;24(1):1170\u20138.","journal-title":"Drug Deliv"},{"issue":"2","key":"627_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1039\/C8NH00417J","volume":"4","author":"L Kong","year":"2019","unstructured":"Kong L, Campbell F, Kros A. DePEGylation strategies to increase cancer nanomedicine efficacy. Nanoscale Horizons. 2019;4(2):378\u201387.","journal-title":"Nanoscale Horizons"},{"issue":"1","key":"627_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12951-020-00599-1","volume":"18","author":"X Li","year":"2020","unstructured":"Li X, et al. Surface chemistry governs the sub-organ transfer, clearance and toxicity of functional gold nanoparticles in the liver and kidney. J Nanobiotechnol. 2020;18(1):45.","journal-title":"J Nanobiotechnol"},{"key":"627_CR21","doi-asserted-by":"crossref","unstructured":"Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145\u2013171.","DOI":"10.1146\/annurev-pathol-121808-102132"},{"key":"627_CR22","doi-asserted-by":"crossref","unstructured":"Lei ZG, et al. CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis. J Hepatol. 2024;80(2).","DOI":"10.1016\/j.jhep.2023.10.025"},{"issue":"3","key":"627_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1152\/physrev.00061.2009","volume":"90","author":"H Malhi","year":"2010","unstructured":"Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: A clear and present danger. Physiol Rev. 2010;90(3):1165\u201394.","journal-title":"Physiol Rev"},{"issue":"25","key":"627_CR24","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3748\/wjg.v24.i25.2661","volume":"24","author":"T Kanda","year":"2018","unstructured":"Kanda T, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol. 2018;24(25):2661\u201372.","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Biological Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13036-026-00627-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-026-00627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-026-00627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:01:52Z","timestamp":1773223312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13036-026-00627-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1186\/s13036-026-00627-y","relation":{},"ISSN":["1754-1611"],"issn-type":[{"value":"1754-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}